{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T15:14:37Z","timestamp":1780586077503,"version":"3.54.1"},"reference-count":69,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1016\/j.critrevonc.2015.01.001","type":"journal-article","created":{"date-parts":[[2015,1,10]],"date-time":"2015-01-10T01:49:23Z","timestamp":1420854563000},"page":"291-301","source":"Crossref","is-referenced-by-count":23,"title":["Recent advances in the treatment of hormone receptor positive HER2 negative metastatic breast cancer"],"prefix":"10.1016","volume":"94","author":[{"given":"Palma","family":"Fedele","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Orlando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Schiavone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Calvani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Caliolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamaria","family":"Quaranta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Nacci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saverio","family":"Cinieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.critrevonc.2015.01.001_bib0350","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1200\/JCO.2010.30.3677","article-title":"Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the tamoxifen and exemestane adjuvant multinational trial","volume":"29","author":"Bartlett","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2015.01.001_bib0355","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1210\/er.2006-0045","article-title":"Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family","volume":"29","author":"Arpino","year":"2008","journal-title":"Endocr Rev"},{"key":"10.1016\/j.critrevonc.2015.01.001_bib0360","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1146\/annurev-med-070909-182917","article-title":"Mechanisms of endocrine resistance in breast cancer","volume":"62","author":"Osborne","year":"2011","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.critrevonc.2015.01.001_bib0365","doi-asserted-by":"crossref","first-page":"838","DOI":"10.2741\/3723","article-title":"Acquired endocrine resistance in breast cancer: implications for tumour metastasis","volume":"16","author":"Hayes","year":"2011","journal-title":"Front Biosci"},{"key":"10.1016\/j.critrevonc.2015.01.001_bib0370","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/nrc2713","article-title":"Biological determinants of endocrine resistance in breast cancer","volume":"9","author":"Musgrove","year":"2009","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2015.01.001_bib0375","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.critrevonc.2012.03.004","article-title":"Targeted agents to reverse resistance to endocrine therapy in metastatic breast cancer: where are we now and where are we going?","volume":"84","author":"Fedele","year":"2012","journal-title":"Crit Rev Oncol Hematol"},{"issue":"5","key":"10.1016\/j.critrevonc.2015.01.001_bib0380","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1634\/theoncologist.2013-0377","article-title":"A targeted next-generation sequencing assay detects a high frequency of therapeutically targetable alterations in primary and metastatic breast cancers: implications for clinical practice","volume":"19","author":"Vasan","year":"2014","journal-title":"Oncologist"},{"key":"10.1016\/j.critrevonc.2015.01.001_bib0385","series-title":"American Association for Cancer Research Annual Meeting 2014","article-title":"Final results of a randomized phase II study of PD 0332991, a cyclin-dependent kinase (CDK)-4\/6 inhibitor, in combination with letrozole vs. letrozole alone for first-line treatment of ER+\/HER2-advanced breast cancer (PALOMA-1; TRIO-18)","author":"Finn","year":"2014"},{"key":"10.1016\/j.critrevonc.2015.01.001_bib0390","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1200\/JCO.2012.43.7251","volume":"10","author":"Yardley","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2015.01.001_bib0395","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/nrclinonc.2010.21","article-title":"mTOR signaling and drug development in cancer","volume":"7","author":"Dancey","year":"2010","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.critrevonc.2015.01.001_bib0400","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1200\/JCO.2008.18.8391","article-title":"Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer","volume":"27","author":"Baselga","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2015.01.001_bib0405","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1200\/JCO.2011.39.0708","article-title":"Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study","volume":"30","author":"Bachelot","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2015.01.001_bib0410","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1109653","article-title":"Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.critrevonc.2015.01.001_bib0415","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.breast.2012.03.003","article-title":"1st International consensus guidelines for advanced breast cancer (ABC 1)","volume":"21","author":"Cardoso","year":"2012","journal-title":"Breast"},{"issue":"5","key":"10.1016\/j.critrevonc.2015.01.001_bib0420","doi-asserted-by":"crossref","first-page":"vii15","DOI":"10.1093\/annonc\/mdq160","article-title":"Locally recurrent or metastatic breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow up","volume":"21","author":"Cardoso","year":"2010","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.critrevonc.2015.01.001_bib0425","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s10549-010-0974-0","article-title":"Systematic review of aromatase inhibitors in the first-line treatment for hormone sensitive advanced or metastatic breast cancer","volume":"123","author":"Riemsma R1","year":"2010","journal-title":"Breast Cancer Res Treat"},{"issue":"30","key":"10.1016\/j.critrevonc.2015.01.001_bib0430","doi-asserted-by":"crossref","first-page":"4883","DOI":"10.1200\/JCO.2007.14.4659","article-title":"Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group","volume":"26","author":"Paridaens","year":"2008","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.critrevonc.2015.01.001_bib0435","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1200\/JCO.2004.02.112","article-title":"Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial","volume":"22","author":"Howell","year":"2004","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.critrevonc.2015.01.001_bib0440","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1200\/JCO.2000.18.7.1399","article-title":"Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group","volume":"18","author":"Kaufmann","year":"2000","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.critrevonc.2015.01.001_bib0445","doi-asserted-by":"crossref","first-page":"3386","DOI":"10.1200\/JCO.2002.10.058","article-title":"Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial","volume":"20","author":"Osborne CK1","year":"2002","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.critrevonc.2015.01.001_bib0450","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1158\/1078-0432.CCR-09-2282","article-title":"Phase II, randomized trial 653 to compare anastrozole combined with gefitinib or placebo in post-menopausal women with hormone receptor-positive metastatic breast cancer","volume":"16","author":"Cristofanilli","year":"2010","journal-title":"J Clin Cancer Res"},{"key":"10.1016\/j.critrevonc.2015.01.001_bib0455","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1158\/1078-0432.CCR-10-1869","article-title":"Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study","volume":"17","author":"Osborne","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"33","key":"10.1016\/j.critrevonc.2015.01.001_bib0460","doi-asserted-by":"crossref","first-page":"5538","DOI":"10.1200\/JCO.2009.23.3734","article-title":"Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for post-menopausal hormone receptor-positive metastatic breast cancer","volume":"27","author":"Johnston","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2015.01.001_bib0465","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1200\/JCO.2011.38.3331","article-title":"Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer","volume":"10","author":"Wolff","year":"2013","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.critrevonc.2015.01.001_bib0470","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1200\/JCO.2011.38.1095","article-title":"FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer","volume":"30","author":"Bergh","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2015.01.001_bib0475","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/S1470-2045(13)70322-X","volume":"14","author":"Johnston","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.critrevonc.2015.01.001_bib0480","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1056\/NEJMoa1201622","article-title":"Combination anastrozole and fulvestrant in metastatic breast cancer","volume":"367","author":"Mehta","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.critrevonc.2015.01.001_bib0485","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1158\/1541-7786.MCR-07-2172","article-title":"An autocrine VEGF\/VEGFR2 and p38 signaling loop confers resistance to 4-hydroxytamoxifen in MCF-7 breast cancer cells","volume":"6","author":"Aesoy","year":"2008","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.critrevonc.2015.01.001_bib0490","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.clbc.2011.03.010","article-title":"Hormonal therapy plus bevacizumab in postmenopausal patients who have hormone receptor positive metastatic breast cancer; a phase II trial of the Sarah Cannon Oncology Research Consortium","volume":"11","author":"Yardley","year":"2011","journal-title":"Clin Breast Cancer"},{"issue":"4","key":"10.1016\/j.critrevonc.2015.01.001_bib0495","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3816\/CBC.2010.n.035","article-title":"Pilot trial of preoperative (Neoadjuvant) letrozole in combination with bevacizumab in postmenopausal women with newly diagnosed estrogen receptor or progesterone receptor positive breast cancer","volume":"10","author":"Forero-Torres","year":"2010","journal-title":"Clin Breast Cancer"},{"issue":"Suppl. 24","key":"10.1016\/j.critrevonc.2015.01.001_bib0500","article-title":"Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer \u2013 first efficacy results from the LEA study","volume":"72","author":"Martin","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.critrevonc.2015.01.001_bib0505","series-title":"Final analysis of the LEA study. 2013 European Cancer Congress","article-title":"Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer","author":"Loibi","year":"2013"},{"key":"10.1016\/j.critrevonc.2015.01.001_bib0510","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.critrevonc.2009.12.004","article-title":"Antiangiogenic strategies in breast cancer management","volume":"76","author":"Giovannini","year":"2010","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.critrevonc.2015.01.001_bib0515","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1007\/s10637-013-9991-2","article-title":"Cediranib in combination with fulvestrant in hormone sensitive metastatic breast cancer; a randomized phase II study","volume":"31","author":"Hyams","year":"2013","journal-title":"Invest New Drugs"},{"issue":"4","key":"10.1016\/j.critrevonc.2015.01.001_bib0520","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1158\/1078-0432.CCR-09-2353","article-title":"AZD8931, an equipotent, reversible, inhibitor of signaling by epidermal growth factor receptor, ERBB2 (Her2), and ERBB3; an unique agent for simultaneous ERBB receptor blockade in cancer","volume":"16","author":"Hickinson","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.critrevonc.2015.01.001_bib0525","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2013.31.15_suppl.531","article-title":"Phase II randomized study of the EGFR, HER2, HER3 signaling inhibitor AZD8931 in combination with anastrozole (A) in women with endocrine therapy (ET) naive advanced breast cancer (MINT)","volume":"31","author":"Johnston","year":"2013","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.critrevonc.2015.01.001_bib0530","doi-asserted-by":"crossref","first-page":"R77","DOI":"10.1186\/bcr2419","article-title":"PD 0332991, a selective cyclin D kinase 4\/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro","volume":"11","author":"Finn","year":"2009","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.critrevonc.2015.01.001_bib0535","series-title":"Proceedings American Association for Cancer Research Annual Meeting 2014","article-title":"Clinical activity of LY2835219, a novel cell cycle inhibitor selective for CDK4 and CDK6, in patients with metastatic breast cancer","author":"Patnaik","year":"2014"},{"key":"10.1016\/j.critrevonc.2015.01.001_bib0540","series-title":"2013 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2013","article-title":"LEE011: an orally bioavailable, selective small molecule inhibitor of CDK4\/6\u2212\u2212 reactivating Rb in cancer","author":"Sunkyu","year":"2013"},{"key":"10.1016\/j.critrevonc.2015.01.001_bib0545","unstructured":"Study of efficacy and safety of LEE011 in postmenopausal women with advanced breast cancer. (MONALEESA-2). NCT01958021. Available from: https:\/\/Clinicaltrials gov."},{"issue":"15s","key":"10.1016\/j.critrevonc.2015.01.001_bib0550","article-title":"Phase I study of PD 0332991, cyclin-D kinase (CDK) 4\/6 inhibitor in combination with letrozole for first-line treatment of patients with ER-positive, HER2-negative breast cancer","volume":"28","author":"Slamon","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2015.01.001_bib0555","unstructured":"A study of palbociclib (PD-0332991)+letrozole vs. letrozole for 1st line treatment of postmenopausal women with ER+\/HER2- advanced breast cancer (PALOMA-2), NCT01740427. https:\/\/clinicaltrials.gov\/."},{"key":"10.1016\/j.critrevonc.2015.01.001_bib0560","unstructured":"A study of palbociclib in addition to standard endocrine treatment in hormone receptor positive Her2 normal patients with residual disease after neoadjuvant chemotherapy and surgery (PENELOPE-B). NCT01864746. Available from: https:\/\/clinicaltrials.gov\/."},{"key":"10.1016\/j.critrevonc.2015.01.001_bib0565","unstructured":"Study of LEE011, BYL719 and letrozole in advanced ER+ breast cancer. NCT01872260. Available from: https:\/\/clinicaltrials.gov\/."},{"issue":"9","key":"10.1016\/j.critrevonc.2015.01.001_bib0570","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1038\/sj.onc.1207315","article-title":"The histone deacetylase inhibitor trichostatin sensitizes estrogen receptor \u03b1- negative breast cancer cells to tamoxifen","volume":"23","author":"Jang","year":"2004","journal-title":"Oncogene"},{"issue":"12","key":"10.1016\/j.critrevonc.2015.01.001_bib0575","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1038\/sj.onc.1209102","article-title":"ER\u03b1 and ER\u03b2 expression and transcriptional activity are differentially regulated by HDAC inhibitors","volume":"25","author":"Duong","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.critrevonc.2015.01.001_bib0580","unstructured":"Exemestane with or without entinostat in treating postmenopausal patients with recurrent hormone receptor positive breast cancer that is locally advanced or metastatic. NCT02115282. Available from: https:\/\/clinicaltrials.gov\/."},{"key":"10.1016\/j.critrevonc.2015.01.001_bib0585","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0092-8674(00)00117-3","article-title":"TOR, a central controller of cell growth","volume":"103","author":"Schmelzle","year":"2000","journal-title":"Cell"},{"issue":"Suppl. 18","key":"10.1016\/j.critrevonc.2015.01.001_bib0590","doi-asserted-by":"crossref","first-page":"3511","DOI":"10.1200\/jco.2007.25.18_suppl.3511","article-title":"The PI3K\/AKT\/mTOR pathway as a target for breast cancer therapy","volume":"25","author":"Di Cosimo","year":"2007","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.critrevonc.2015.01.001_bib0595","first-page":"476","article-title":"Mammalian target of rapamycin: a central node of complex signaling cascades","volume":"4","author":"Dobashi","year":"2011","journal-title":"Int J Clin Exp Pathol"},{"issue":"23","key":"10.1016\/j.critrevonc.2015.01.001_bib0600","doi-asserted-by":"crossref","first-page":"8059","DOI":"10.1158\/1078-0432.CCR-04-0035","article-title":"Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt activity","volume":"10","author":"De Graffenried","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.critrevonc.2015.01.001_bib0605","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s10549-013-2810-9","article-title":"A phase II study of combined fulvestrant and everolimus in patients with metastatic estrogen receptor (ER)-positive breast cancer after aromatase inhibitor (AI) failure","volume":"143","author":"Massarweh","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.critrevonc.2015.01.001_bib0610","series-title":"European Multidisciplinary Cancer Congress (EMCC) 2011","article-title":"Everolimus in combination with exemestane for postmenopausal women with advanced breast cancer who are refractory to letrozole or anastrozole: results of the BOLERO-2 phase III trial","author":"Baselga","year":"2011"},{"issue":"Suppl. 24","key":"10.1016\/j.critrevonc.2015.01.001_bib0615","first-page":"S3","article-title":"Everolimus for postmenopausal women with advanced breast cancer: updated results of the BOLERO-2 Phase III Trial","volume":"71","author":"Hortobagy","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2015.01.001_bib0620","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1007\/s12325-013-0060-1","article-title":"Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis","volume":"30","author":"Yardley","year":"2013","journal-title":"Adv Ther"},{"key":"10.1016\/j.critrevonc.2015.01.001_bib0625","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1200\/JCO.2007.13.5822","article-title":"Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT","volume":"26","author":"Chia","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2015.01.001_bib0630","series-title":"SABCS 2013","article-title":"Characterization of response to everolimus (EVE) in BOLERO-2: a phase 3 trial of EVE plus exemestane (EXE) in postmenopausal women with HR+, HER2- advanced breast cancer","author":"Burris","year":"2013"},{"key":"10.1016\/j.critrevonc.2015.01.001_bib0635","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1016\/j.ejca.2013.04.011","article-title":"Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: subgroup analysis from the BOLERO-2 study","volume":"49","author":"Campone","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.critrevonc.2015.01.001_bib0640","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2013.31.26_suppl.152","article-title":"BOLERO-2: efficacy and safety of first-line everolimus plus exemestane in advanced breast cancer","volume":"31","author":"Rugo","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2015.01.001_bib0645","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1002\/cncr.28010","article-title":"Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial","volume":"119","author":"Burris","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2015.01.001_bib0650","unstructured":"Open-label, phase II, study of everolimus plus letrozole in postmenopausal women with ER+, HER2- metastatic or locally advanced breast cancer (Bolero-4), NCT01698918. Available from: https:\/\/Clinicaltrials gov."},{"key":"10.1016\/j.critrevonc.2015.01.001_bib0655","unstructured":"Hormone therapy with or without everolimus in treating patients with breast cancer, NCT01674140 US. Available from: https:\/\/Clinicaltrials gov."},{"key":"10.1016\/j.critrevonc.2015.01.001_bib0660","unstructured":"Safety study of mTOR inhibitors everolimus to adjuvant hormone therapy in women with poor prognosis, ER-positive and HER2-negative primary breast cancer, free of disease after receiving 3 years of adjuvant hormone therapy, NCT01805271. Available from: https:\/\/Clinicaltrials gov."},{"key":"10.1016\/j.critrevonc.2015.01.001_bib0665","unstructured":"A Phase II study of eveIrolimus in combination with exemestane versus everolimus alone versus capecitabine in advanced breast cancer. NCT01783444. Available from: https:\/\/Clinicaltrials gov."},{"key":"10.1016\/j.critrevonc.2015.01.001_bib0670","unstructured":"Study of Fulvestrant\u00b1everolimus in postmenopausal, hormone receptor positive metastatic breast cancer resistant to aromatase inhibitors. NCT01797120. Available from: https:\/\/Clinicaltrials gov."},{"key":"10.1016\/j.critrevonc.2015.01.001_bib0675","unstructured":"Phase III study of BKM120\/placebo with fulvestrant in postmenopausal patients with hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer refractory to aromatase inhibitor. BELLE2. NCT01610284. Available from: https:\/\/Clinicaltrials gov."},{"key":"10.1016\/j.critrevonc.2015.01.001_bib0680","unstructured":"A study of Ridaforolimus (MK-8669) in combination with Dalotuzumab (MK-0646) compared to standard of care treatment in estrogen receptor positive breast cancer patients. NCT01234857. Available from: https:\/\/Clinicaltrials gov."},{"key":"10.1016\/j.critrevonc.2015.01.001_bib0685","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2013.31.15_suppl.510","article-title":"Predictive markers of everolimus efficacy in hormone receptor positive (HR+) metastatic breast cancer (MBC): final results of the TAMRAD trial translational study","volume":"31","author":"Treilleux","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2015.01.001_bib0690","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2013.31.18_suppl.lba509","article-title":"Correlation of molecular alterations with efficacy of everolimus in hormone receptor\u2013positive, HER2-negative advanced breast cancer: results from BOLERO-2","volume":"31","author":"Hortobagyi","year":"2013","journal-title":"J Clin Oncol"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842815000025?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842815000025?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,28]],"date-time":"2020-08-28T21:10:36Z","timestamp":1598649036000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842815000025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":69,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["S1040842815000025"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2015.01.001","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]}}}